IJAA Editor's Choice April

Two articles have been chosen for April's Editor's Choice section by Jean-Marc Rolain, Editor of the International Journal of Antimicrobial Chemotherapy. Read them for free for a limited time.

Faecal microbiota transplantation shortens the colonisation period and allows re-entry of patients carrying carbapenamase-producing bacteria into medical care facilities by Saïdani et al

Editor's Comment:

"In this study, Saidani et al. evaluated the impact of fecal microbiota transplantation (FMT) for the decolonization of patients carrying carbapenemase-producing bacteria. They demonstrated a significant reduction of the bacterial carriage at day 14 post-FMT as compared to the control group (p<0.001). The median decolonization period was reduced from 50.5 days to 3 days, which led to a reduced length of stay at hospital (77 days to 10 days). 

They concluded that FMT should be associated with high-dose antibiotic treatment and efficient bowel washes to increase its success. This strategy has to be included in a rigorous decontamination of other carriage sites and direct patient environment. This article is of concern as the management of such patients is a public health concern. Indeed, the need for strict isolation procedures and the inability to accept such patients in some structures are complicated for both patient and medical team." 

Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo by Zeng et al.

Editor's Comment:

"In this study, Zeng et al. have tested the activity of two macrolide compounds, spiramycin and azithromycin, against enterovirus A71 in an in vitro and in an in vivo model. The team investigated all stages of antibiotic characteristics, including in vitro activity, mechanism of action, resistance and in vivo efficacy. They established that these antibiotics act on the virus mainly by inhibiting replication at post-entry stage by repressing viral RNA synthesis directly or indirectly. Mutations inducing resistance to both antibiotics were also observed in highly conserved regions related to RNA replication. Finally, azithromycin improved the survival rate and disease manifestation in a mouse model of severe EV-A71 infection. This example of drug repurposing is promising for the treatment of enterovirus infection as azithromycin is currently available and safe to administrate in children."

 

Back to News